| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 16, 2026 | Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway | Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway
Mon, Mar 16, 2026 17:00 CET Report this content
Press Release – Oslo, Norway, M... |
| Feb 27, 2026 | ImmVira's Oncolytic Product MVR-T3011 Expanded to BCG-Naïve Bladder Cancer Patients for the First Time with Clinical Data Presented at the 2026 ASCO GU Conference | SUZHOU, China, Feb. 27, 2026 /PRNewswire/ -- Intravesical BCG is the standard of care (SOC) for BCG-naïve high-risk non-muscle-invasive bladder cancer (NMIBC) patients. However, the scarcity of BCG products has become a global phenomenon, a... |
| Jan 12, 2026 | New publication of Hexvix trial data from China: blue light cystoscopy with Hexvix significantly improves the detection of bladder cancer using modern HD equipment | New publication of Hexvix trial data from China: blue light cystoscopy with Hexvix significantly improves the detection of bladder cancer using modern HD equipment
Mon, Jan 12, 2026 17:00 CET Report this content
Press release – Oslo, Norway... |
| Jun 23, 2025 | How Philanthropy Powers Cutting-Edge Science | Christian May, City AM‘s Editor in Chief, meets experts from Cancer Research UK and the Francis Crick Institute to explore the role of philanthropy in driving breakthrough research and treatment.
Cancer remains a formidable challenge. Globa... |
| May 27, 2025 | Dermalyser Receives CE Mark In Europe, Paving Way to Market for World’s Best Melanoma Diagnostic Decision Support Tool | Dermalyser Receives CE Mark In Europe, Paving Way to Market for World’s Best Melanoma Diagnostic Decision Support Tool
Tue, May 27, 2025 07:30 CET Report this content
Dermalyser significantly outperforms experienced dermatologists at detect... |
| Apr 29, 2025 | Bladder Cancer presentations at AUA2025: Blue Light Cystoscopy improves risk stratification and informed decision making | Bladder Cancer presentations at AUA2025: Blue Light Cystoscopy improves risk stratification and informed decision making
Tue, Apr 29, 2025 08:00 CET Report this content
Press Release – Oslo, Norway, April 29, 2025: Photocure ASA (OSE: PHO),... |
| Mar 26, 2025 | Photocure appoints Jane Healy as Vice President and General Manager EMEA | Photocure appoints Jane Healy as Vice President and General Manager EMEA
Wed, Mar 26, 2025 08:00 CET Report this content
Press Release – Oslo, Norway, March 26, 2025: Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced the... |
| Mar 26, 2025 | Photocure ASA - Share option grant to Vice President and General Manager EMEA | Photocure ASA - Share option grant to Vice President and General Manager EMEA
Wed, Mar 26, 2025 08:55 CET Report this content
Oslo, Norway, 26 March 2025 - Photocure ASA (the "Company") (OSE: PHO) has granted share options to Jane... |
| Feb 18, 2025 | AstraZeneca's Board Transformation: A New Era in Cancer Care | AstraZeneca is undergoing a significant transformation. The biopharmaceutical giant is set to welcome Karen Knudsen as a Non-Executive Director. This move is more than just a boardroom shuffle; it’s a strategic play in the complex game of c... |
| Feb 17, 2025 | News on Richard Wolf/Photocure Collaboration: Interim Flexible BLC solution available in countries where System blue and Richard Wolf reusable flexible cystoscopes are cleared | News on Richard Wolf/Photocure Collaboration: Interim Flexible BLC solution available in countries where System blue and Richard Wolf reusable flexible cystoscopes are cleared
Mon, Feb 17, 2025 17:00 CET Report this content
Press Release – ... |
| Jan 14, 2025 | HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC | — Indication expands to include treatment-naïve patients —
— The 2021 conditional approval in previously treated patients converted to full approval —
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED... |
| Jan 2, 2025 | HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for the combination of ORPATHYS® (savolit... |
| Dec 7, 2024 | Fosun International: A Beacon of ESG Excellence Amidst Global Challenges | In a world where corporate responsibility often feels like a buzzword, Fosun International Limited stands out like a lighthouse in a storm. Recently, the Hong Kong-based conglomerate secured five prestigious Environmental, Social, and Gover... |
| Dec 4, 2024 | Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer | SAN FRANCISCO, U.S. and SUZHOU, China, Dec. 4, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines... |
| Oct 22, 2024 | Swedish AI Medical Technologies now receives approval to trial AI for determining actual melanoma thickness prior to surgery | Swedish AI Medical Technologies now receives approval to trial AI for determining actual melanoma thickness prior to surgery
Tue, Oct 22, 2024 09:10 CET Report this content
Dermalyser support tool has already demonstrated 100% sensitivity a... |
| Aug 30, 2024 | HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 30, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has voluntarily withdrawn its supplemental New Drug Application (“NDA... |
| Jul 4, 2024 | HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status | HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 04, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for tazemetostat for the treatment of a... |
| Jul 1, 2024 | Lynparza & Imfinzi positive CHMP in endometrial | Lynparza & Imfinzi positive CHMP in endometrial
Mon, Jul 01, 2024 08:00 CET Report this content
1 July 2024
Lynparza and Imfinzi combination recommended for approval in the EU by CHMP for patients with mismatch repair proficient advance... |
| Jun 17, 2024 | Imfinzi approved in the US for endometrial cancer | Imfinzi approved in the US for endometrial cancer
Mon, Jun 17, 2024 08:00 CET Report this content
17 June 2024
Imfinzi plus chemotherapy approved in the US for
mismatch repair deficient advanced or recurrent endometrial cancer
Approval base... |
| Jun 4, 2024 | Photocure Announces Mobile BLC Tower Initiative to Expand Access to Cysview in the U.S. | Photocure Announces Mobile BLC Tower Initiative to Expand Access to Cysview in the U.S.
Tue, Jun 04, 2024 08:00 CET Report this content
Press Release – Oslo, Norway, June 4, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, today ... |
| May 14, 2024 | Swedish skin cancer diagnostic start-up AI Medical Technology has completed the latest stage in its ongoing strategic transformation, appointing two renowned executives to its board. | Swedish skin cancer diagnostic start-up AI Medical Technology has completed the latest stage in its ongoing strategic transformation, appointing two renowned executives to its board.
Tue, May 14, 2024 08:00 CET Report this content
Stockholm... |
| May 7, 2024 | Bladder Cancer: Long-Term Benefits of Blue Light Cystoscopy and Enhanced Detection with HD Technology Unveiled at AUA 2024 | Bladder Cancer: Long-Term Benefits of Blue Light Cystoscopy and Enhanced Detection with HD Technology Unveiled at AUA 2024
Tue, May 07, 2024 08:00 CET Report this content
Press Release – Oslo, Norway, May 7, 2024: Photocure ASA (OSE: PHO), ... |
| Apr 30, 2024 | Bladder Cancer: pivotal trial results and new real-world evidence, to be presented at AUA 2024, demonstrate improved diagnostic and clinical outcomes with blue light cystoscopy | Bladder Cancer: pivotal trial results and new real-world evidence, to be presented at AUA 2024, demonstrate improved diagnostic and clinical outcomes with blue light cystoscopy
Tue, Apr 30, 2024 07:30 CET Report this content
Press Release –... |
| Apr 29, 2024 | Skin cancer diagnostic company AI Medical Technology raises SEK12m (US$1m) via an oversubscribed bridge financing round in anticipation of a significant Series A later this year | Skin cancer diagnostic company AI Medical Technology raises SEK12m (US$1m) via an oversubscribed bridge financing round in anticipation of a significant Series A later this year
Mon, Apr 29, 2024 08:00 CET Report this content
Stockholm, Swe... |
| Apr 24, 2024 | US regulator accepts GSK’s application to expand treatment of cancer drug | The Food and Drug Administration (FDA) has accepted GSK’s application to expand treatment of its cancer-fighting technology, Jemperli.
The treatment, Jemperli, will now be classed as being able to help all adult patients with primary advanc... |
| Apr 8, 2024 | European Association of Urology (EAU) 2024 congress features new data on modern technology use in bladder cancer care | European Association of Urology (EAU) 2024 congress features new data on modern technology use in bladder cancer care
Mon, Apr 08, 2024 12:32 CET Report this content
Press Release – Oslo, Norway, April 8, 2024: Photocure ASA (OSE: PHO), the... |
| Apr 2, 2024 | Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status | ROCKVILLE, Md. and SUZHOU, China, April 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| Mar 28, 2024 | New Publication: Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy | New Publication: Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy
Thu, Mar 28, 2024 13:13 CET Report this content
Press release – Oslo, Norway, March 28, 2024: Photocure ASA, The Bladder Cancer Company, anno... |
| Mar 27, 2024 | Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy | ROCKVILLE, Md. and SUZHOU, China, March 27, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines fo... |
| Mar 6, 2024 | New Swedish clinical study published in the British Journal of Dermatology demonstrates superiority of AI-algorithm guided melanoma diagnosis | New Swedish clinical study published in the British Journal of Dermatology demonstrates superiority of AI-algorithm guided melanoma diagnosis
Wed, Mar 06, 2024 08:30 CET Report this content
Dermalyser AI-driven support tool achieved remarka... |
| Feb 1, 2024 | New cancer cases to increase 77% by 2050, WHO estimates | The World Health Organization predicts we will see more than 35 million new cancer cases by 2050, a 77% increase from the estimated 20 million cases in 2022.
The data comes from a report the organization's cancer agency, the International A... |
| Jan 16, 2024 | Preliminary results of DigniCap Delta study demonstrate 79 percent efficacy | Preliminary results of DigniCap Delta study demonstrate 79 percent efficacy
Tue, Jan 16, 2024 10:14 CET Report this content
Dignitana announces that the Hospital de Clínicas in Montevideo, Uruguay has completed the first stage of a two-year... |
| Dec 27, 2023 | Boan Biotech's Two Innovative Drugs Targeting Claudin 18.2 Granted ODD by FDA | YANTAI, China, Dec. 27, 2023 /PRNewswire/ -- Boan Biotech today announced that two of its Claudin18.2-targeted investigational drugs have been granted the Orphan Drug Designation (ODD) for the treatment of pancreatic cancer by the U.S. Food... |
| Nov 14, 2023 | Update on PACIFIC-2 Phase III trial for Imfinzi | Update on PACIFIC-2 Phase III trial for Imfinzi
Tue, Nov 14, 2023 08:05 CET Report this content
14 November 2023
Update on PACIFIC-2 Phase III trial of Imfinzi concurrently administered with platinum-based chemoradiotherapy in unresectable,... |
| Nov 8, 2023 | Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer | ORSERDU is the first treatment specifically approved for patients with ER+, HER2- advanced or metastatic breast cancer tumors that harbor ESR1 mutations, representing the first innovation in endocrine therapy in nearly 20 years.
ESR1 mutati... |
| Nov 2, 2023 | European Medicines Agency validates Pierre Fabre Laboratories' marketing authorisation application for combination BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) for patients with BRAFV600-mutant advanced non-small cell lung cancer (NSCLC) | - BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) shows meaningful clinical benefit in adult patients with BRAFV600-mutant advanced NSCLC
- The application is based on results from the PHAROS study,[1] which showed an objective response ra... |
| Nov 2, 2023 | アストラゼネカ、肺がん啓発プロジェクト「知ってもらいたい、肺がんのこと。」河村隆一さんによる初の完全オリジナル楽曲「何気ないその笑顔が...」11月2日(木)公開 | アストラゼネカ株式会社（本社：大阪市北区、代表取締役社長：堀井 貴史、以下、アストラゼネカ）は11月の肺がん啓発月間における取り組みの一環として、肺がん治療経験のあるアーティスト河村隆一さんが、ご自身の経験や肺がん患者さんの声をもとに制作した、完全オリジナル応援ソング「何気ないその笑顔が...」をプロジェクト公式サイト（https://www.haigan-tomoni.jp/haigan_kenshin/project_k/）にて11月2日（木）より公開します。また、楽曲制... |
| Sep 15, 2023 | Enhertu recommended in EU for HER2-mutant NSCLC | Enhertu recommended in EU for HER2-mutant NSCLC
Fri, Sep 15, 2023 16:00 CET Report this content
15 September 2023
Enhertu recommended for approval in the EU by CHMP for
patients with HER2-mutant advanced non-small cell lung cancer
Recommend... |
| Jul 3, 2023 | Dato-DXd significantly improved PFS in lung cancer | Dato-DXd significantly improved PFS in lung cancer
Mon, Jul 03, 2023 08:00 CET Report this content
This announcement contains inside information
3 July 2023
Datopotamab deruxtecan met dual primary endpoint of
progression-free survival in pa... |
| Jun 27, 2023 | EXCELLENT CLINICAL DATA FOR SUBB2M/CA15-3 BREAST CANCER TEST | INOVIQ's SubB2M/CA15-3 breast cancer test detects all-stages of breast cancer with excellent accuracy (87%), sensitivity (81%) and specificity (93%)
The results of a comprehensive 483-sample case-control study established that INOVIQ's SubB... |
| Jun 5, 2023 | Innovent Presents Phase 1b Clinical Data of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2023 ASCO Annual Meeting | ROCKVILLE, Md. and SUZHOU, China, June 5, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| Jun 2, 2023 | Imfinzi improved pCR in gastric and GEJ cancers | Imfinzi improved pCR in gastric and GEJ cancers
Fri, Jun 02, 2023 18:00 CET Report this content
2 June 2023
Imfinzi plus chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers in MA... |
| May 30, 2023 | Guardant Health Receives Regulatory Approval from Singapore's Health Sciences Authority for Guardant360® CDx blood test for patients with advanced solid cancers | Guardant360® CDx is a comprehensive genomic profiling blood test that provides critical information to help inform personalized treatment decisions for patients with advanced solid cancers
The liquid biopsy test is also approved as a compan... |
| May 26, 2023 | Imfinzi plus Lynparza and Imfinzi alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy | Imfinzi plus Lynparza and Imfinzi alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy
Fri, May 26, 2023 08:00 CET Report this content
26 May 2023
Imfinzi plus Lynparza and Im... |
| May 2, 2023 | Photocure: Nordic registry clinical data and multiple scientific programs at AUA 2023 Congress reinforce the benefits of Blue Light Cystoscopy | OSLO, Norway, May 2, 2023 /PRNewswire/ -- Photocure ASA PHO, the Bladder Cancer Company, announces that results from the Nordic Registry demonstrating benefits of Blue Light Cystoscopy (BLC®) were presented at the AUA 2023 Conference: the A... |
| Apr 12, 2023 | Specialised Therapeutics signs partnership agreement with Akeso Inc. and CTTQ-Akeso to commercialise new anti-PD1 antibody in Australia and Southeast Asia | SINGAPORE, April 12, 2023 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner with CTTQ-Akeso (Shanghai) Biomed. Tech. Co., Ltd. (CTTQ-Akeso)（jointly established by Akeso, Inc. (9926... |
| Apr 11, 2023 | Boan Biotech's Biologics License Application for Boyounuo® (Bevacizumab Injection) Accepted in Brazil | YANTAI, China, April 11, 2023 /PRNewswire/ -- Boan Biotech today announced that Brazil's Agência Nacional de Vigilância Sanitária (ANVISA) has accepted the company's Biologics License Application (BLA) for Boyounuo® (Bevacizumab Injection).... |
| Mar 30, 2023 | AstraZeneca completes KYM agreement for CMG901 | AstraZeneca completes KYM agreement for CMG901
Thu, Mar 30, 2023 08:00 CET Report this content
30 March 2023 07:00 BST
License agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate, completed
AstraZeneca has comp... |
| Mar 27, 2023 | Phase III RUBY clinical trial demonstrates potential of Jemperli (dostarlimab-gxly) plus chemotherapy to redefine the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone | 72% and 36% reduction in the risk of disease progression or death observed in the dMMR/MSI-H population and overall patient population, respectively Clinically meaningful overall survival trend observed at interim analysis Results presented... |
| Mar 9, 2023 | Imfinzi improved EFS in resectable lung cancer | Imfinzi improved EFS in resectable lung cancer
Thu, Mar 09, 2023 08:00 CET Report this content
9 March 2023 07:00 GMT
Imfinzi significantly improved event-free survival in AEGEAN
Phase III trial for patients with resectable non-small cell l... |
| Feb 23, 2023 | AstraZeneca enters agreement with KYM for CMG901 | AstraZeneca enters agreement with KYM for CMG901
Thu, Feb 23, 2023 08:00 CET Report this content
23 February 2023 07:00 GMT
AstraZeneca enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate
CMG901 ... |
| Feb 10, 2023 | US FDA grants regular approval for Jemperli for the treatment of patients with recurrent or advanced mismatch repair-deficient endometrial cancer | Conversion from accelerated to regular (full) approval based on long-term outcomes from the GARNET phase I trial, which demonstrated an overall response rate of 45.4% 85.9% of patients had duration of response ≥12 months and 54.7% of patien... |
| Feb 7, 2023 | AI Medical Technology reports highly promising results from clinical study in primary care facilities to validate Dermalyser – an AI-driven support tool for diagnosing melanoma skin cancer | AI Medical Technology reports highly promising results from clinical study in primary care facilities to validate Dermalyser – an AI-driven support tool for diagnosing melanoma skin cancer
Tue, Feb 07, 2023 09:00 CET Report this content
Fir... |
| Feb 6, 2023 | Personal story leads entrepreneur to launch a startup to improve cancer care in Africa and beyond | Hurone AI founder Kingsley Ndoh. (Hurone Photo)
Seattle entrepreneur Kingsley Ndoh is driven by the memory of his aunt, who died too young of colon cancer.
A lot of things went wrong when she was sick more than ten years ago in Nigeria, sai... |
| Jan 24, 2023 | AI Medical Technology nets SEK10.8 million to accelerate Dermalyser AI-driven diagnostic support tool for skin cancer | AI Medical Technology nets SEK10.8 million to accelerate Dermalyser AI-driven diagnostic support tool for skin cancer
Tue, Jan 24, 2023 08:30 CET Report this content
Northern CapSek Ventures takes part in oversubscribed investment round
Fir... |
| Dec 28, 2022 | Imfinzi, Imjudo approved in Japan for 3 cancers | Imfinzi, Imjudo approved in Japan for 3 cancers
Wed, Dec 28, 2022 08:00 CET Report this content
28 December 2022 07:00 GMT
Imfinzi plus Imjudo approved in Japan for advanced liver and non-small cell lung cancers, and Imfinzi approved for un... |
| Dec 21, 2022 | Lynparza approved in EU for prostate cancer | Lynparza approved in EU for prostate cancer
Wed, Dec 21, 2022 08:05 CET Report this content
21 December 2022 07:05 GMT
Lynparza in combination with abiraterone approved in the EU as 1st-line treatment for patients with metastatic castration... |
| Dec 19, 2022 | Imfinzi + Imjudo recommended for approvals in EU | Imfinzi + Imjudo recommended for approvals in EU
Mon, Dec 19, 2022 08:10 CET Report this content
19 December 2022 07:10 GMT
Imfinzi plus Imjudo recommended for approval in the EU
by CHMP for the treatment of advanced liver and lung cancers
... |
| Dec 19, 2022 | Enhertu approved in EU for gastric cancer | Enhertu approved in EU for gastric cancer
Mon, Dec 19, 2022 08:15 CET Report this content
19 December 2022 07:15 GMT
Enhertu approved in the EU for patients with previously treated HER2-positive advanced gastric cancer
First HER2-directed m... |
| Dec 19, 2022 | Enhertu recommended for EU approval in HER2-low BC | Enhertu recommended for EU approval in HER2-low BC
Mon, Dec 19, 2022 08:20 CET Report this content
19 December 2022 07:20 GMT
Enhertu recommended for approval in the EU by CHMP for patients
with HER2-low metastatic breast cancer
AstraZeneca... |
| Dec 19, 2022 | Update on Imfinzi PEARL trial | Update on Imfinzi PEARL trial
Mon, Dec 19, 2022 08:05 CET Report this content
19 December 2022 07:05 GMT
Update on PEARL Phase III trial of Imfinzi monotherapy
in Stage IV non-small cell lung cancer
The PEARL Phase III trial for AstraZeneca... |
| Nov 16, 2022 | SLACOM and NCCN Launch International Project to Improve Breast Cancer Care in Argentina | National Comprehensive Cancer Network and the Latin American and Caribbean Society of Medical Oncology collaborate to address policy and practice solutions to increase equitable access for breast cancer care, starting in Argentina and then ... |
| Nov 14, 2022 | Enhertu recommended for EU approval in gastric | Enhertu recommended for EU approval in gastric
Mon, Nov 14, 2022 08:10 CET Report this content
14 November 2022 07:10 GMT
Enhertu recommended for approval in the EU by CHMP for patients with previously treated HER2-positive advanced gastric... |
| Nov 14, 2022 | Lynparza combo recommended in the EU for mCRPC | Lynparza combo recommended in the EU for mCRPC
Mon, Nov 14, 2022 08:00 CET Report this content
14 November 2022 07:00 GMT
Lynparza in combination with abiraterone recommended for approval
in the EU by CHMP as 1st-line treatment for patients... |
| Nov 11, 2022 | Imfinzi + Imjudo approved in US for lung cancer | Imfinzi + Imjudo approved in US for lung cancer
Fri, Nov 11, 2022 08:00 CET Report this content
11 November 2022 07:00 GMT
Imfinzi and Imjudo with chemotherapy approved in the US
for patients with metastatic non-small cell lung cancer
Appro... |
| Nov 2, 2022 | AI Medical Technology receives ISO 13485:2016 certification | AI Medical Technology receives ISO 13485:2016 certification
Wed, Nov 02, 2022 08:30 CET Report this content
Clinical study in Swedish primary care facilities to validate Dermalyser AI-driven decision support tool for diagnosing malignant me... |
| Nov 1, 2022 | Accuray Announces Tomo® C Registration Submission to China's National Medical Products Administration | SUNNYVALE, Calif., Nov. 1, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the registration dossier for the CNNC-Accuray joint venture Tomo® C radiation therapy system for the Type B market has been submitted t... |
| Oct 18, 2022 | CARsgen Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA | SHANGHAI, Oct. 18, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the Nat... |
| Oct 14, 2022 | Novartis receives positive CHMP opinion for Pluvicto® for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer | Phase III VISION trial showed Pluvicto® plus best standard of care significantly improved survival for patients with pre-treated PSMA-positive mCRPC1
Approximately 473,000 prostate cancer cases and 108,000 prostate cancer-related deaths occ... |
| Sep 1, 2022 | Understanding blood cancers, and how treatment advances offer hope | Blood cancer affects people across all ages and genders. However, awareness of the disease remains low due to its disparate nature.
“Many people think that there’s only one type of blood cancer; they are more aware of other common cancers s... |
| Aug 25, 2022 | Lynparza approved in Japan for early breast cancer | Lynparza approved in Japan for early breast cancer
Thu, Aug 25, 2022 08:00 CET Report this content
25 August 2022 07:00 BST
Lynparza approved in Japan as adjuvant treatment for patients
with BRCA-mutated HER2-negative high-risk early breast... |
| Aug 4, 2022 | Lynparza approved in EU for early breast cancer | Lynparza approved in EU for early breast cancer
Thu, Aug 04, 2022 08:00 CET Report this content
4 August 2022 07:00 BST
Lynparza approved in the EU as adjuvant treatment for patients with
germline BRCA-mutated HER2-negative high-risk early ... |
| Jul 21, 2022 | Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO® (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy | – Based on Results from Phase 3 BOSTON Study, Marketing Authorisation Expands Multiple Myeloma Indication –
– Approval Follows Positive Opinion by European Committee for Medicinal Products for Human Use (CHMP) in May 2022 –
NEWTON, Mass. an... |
| Jul 19, 2022 | Enhertu approved in the EU for patients with HER2-positive metastatic breast cancer treated with one or more prior anti-HER2-based regimens | Enhertu approved in the EU for patients with HER2-positive metastatic breast cancer treated with one or more prior anti-HER2-based regimens
Tue, Jul 19, 2022 08:01 CET Report this content
Approval broadens indication for AstraZeneca and Dai... |
| Jul 19, 2022 | Enhertu approved in EU for HER2-positive mBC | Enhertu approved in EU for HER2-positive mBC
Tue, Jul 19, 2022 08:17 CET Report this content
19 July 2022 07:00 BST
Enhertu approved in the EU for patients with HER2-positive metastatic breast cancer treated with one or more prior anti-HER2... |
| Jul 6, 2022 | Guardant Health and Adicon announce strategic partnership to offer comprehensive genomic profiling tests to accelerate development of new cancer therapies in China | Collaboration will provide biopharmaceutical companies access to Guardant Health's broad portfolio of cancer tests to help advance drug development programs and their clinical trials
SINGAPORE, July 6, 2022 /PRNewswire/ -- Guardant Health, ... |
| Jun 30, 2022 | Imfinzi improved pCR in resectable lung cancer | Imfinzi improved pCR in resectable lung cancer
Thu, Jun 30, 2022 08:00 CET Report this content
30 June 2022 07:00 BST
Imfinzi plus chemotherapy significantly improved pathologic complete response in AEGEAN Phase III trial in resectable non-... |
| Jun 27, 2022 | Enhertu recommended for breast cancer EU approval | Enhertu recommended for breast cancer EU approval
Mon, Jun 27, 2022 08:05 CET Report this content
27 June 2022 07:05 BST
Enhertu recommended for approval in the EU by CHMP for patients with HER2-positive metastatic breast cancer treated wit... |
| Jun 27, 2022 | Lynparza recommended in EU for early breast cancer | Lynparza recommended in EU for early breast cancer
Mon, Jun 27, 2022 08:00 CET Report this content
27 June 2022 07:00 BST
Lynparza recommended for approval in the EU by CHMP as adjuvant treatment for patients with germline BRCA-mutated HER2... |
| Jun 6, 2022 | PADCEV™ (enfortumab vedotin) treatment for Locally Advanced or Metastatic Urothelial Cancer receives market authorisation in Singapore | Enfortumab vedotin is the first antibody drug conjugate approved in Singapore for la/mUC patients who received a prior platinum-containing chemotherapy and a PD-1/L1 inhibitor.
SINGAPORE – Media OutReach – 6 June 2022 – Astellas Pharma Inc.... |
| May 24, 2022 | Pierre Fabre and EORTC open a large Phase III clinical study in the adjuvant setting of stage IIB-C melanoma | First study conducted in the adjuvant setting with a combination of BRAF and MEK inhibitors in high-risk stage II BRAF V600E/K-mutant cutaneous melanoma
A global partnership between EORTC and Pierre Fabre to advance research in melanoma
CAS... |
| May 21, 2022 | Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma | -- European Commission Decision Anticipated within Approximately 60 Days --
NEWTON, Mass. and FLORENCE, Italy, May 21, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering no... |
| May 2, 2022 | Swedish start-up AI Medical Technology initiates clinical study in primary care facilities to validate Dermalyser – an AI-driven support tool for diagnosing malignant melanoma | Swedish start-up AI Medical Technology initiates clinical study in primary care facilities to validate Dermalyser – an AI-driven support tool for diagnosing malignant melanoma
Mon, May 02, 2022 08:00 CET Report this content
Stockholm, Swede... |
| Mar 24, 2022 | Update on CALLA Phase III trial for Imfinzi | Update on CALLA Phase III trial for Imfinzi
Thu, Mar 24, 2022 08:00 CET Report this content
24 March 2022 07:00 GMT
Update on CALLA Phase III trial of concurrent use of Imfinzi
and chemoradiotherapy in locally advanced cervical cancer
The C... |
| Mar 14, 2022 | CStone announces the NMPA approval of GAVRETO (pralsetinib) for the treatment of Advanced or Metastatic RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer | GAVRETO is the first and only selective rearranged during transfection (RET) inhibitor approved in China for the treatment of RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer (TC)
The labeled indications of G... |
| Mar 14, 2022 | Guardant Health Receives Regulatory Approval for Guardant360 CDx in Japan | TOKYO, March 14, 2022 /PRNewswire/ -- The Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval of Guardant360® CDx, a liquid biopsy test for tumor mutation profiling, also known as comprehensive genomic profiling (C... |
| Feb 17, 2022 | CStone Pharmaceuticals Announces the Acceptance of New Drug Application (NDA) for Pralsetinib for the Treatment of RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) and RET-Altered Thyroid Cancers in Taiwan, China | SUZHOU, China, Feb. 17, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and pr... |
| Feb 15, 2022 | Lynparza combo delays progression risk in prostate | Lynparza combo delays progression risk in prostate
Tue, Feb 15, 2022 08:00 CET Report this content
15 February 2022 07:00 GMT
Lynparza plus abiraterone reduced risk of disease progression by 34% vs. standard-of-care in 1st-line metastatic c... |
| Feb 11, 2022 | Photocure Partner Asieris announces Approval to conduct a Phase III Clinical Trial for Hexvix in China | Oslo, Norway, February 11, 2022: Photocure ASA (PHO: OSE), The Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has obtained the Phase III clinical trial application (CTA) approval from the National M... |
| Feb 10, 2022 | Genetron Health Announces Companion Diagnostic Collaboration Agreement with HUTCHMED's ORPATHYS® for NSCLC | BEIJING, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early can... |
| Feb 7, 2022 | Bladder Cancer technology: New improved Blue Light Cystoscopy system receives FDA approval for use in NMIBC in the U.S. | Oslo, Norway, February 7, 2022: Photocure ASA, The Bladder Cancer Company, announces U.S. Food and Drug Administration (FDA) approval of a new and improved Blue Light system to be used with Photocure's Cysview® product in Blue Light Cystosc... |
| Feb 3, 2022 | ONO and Bristol Myers Squibb Sign Outsourcing Agreement with PRiME-R on Clinical Research of Opdivo in Patients with Gastric Cancer, utilizing CyberOncology in Japan | Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director,
Gyo Sagara; 'ONO') and Bristol-Myers Squibb K.K. (Tokyo, Japan; President,
Jean-Christophe Barland) announced that the companies have signed an outsourcing agre... |
| Feb 1, 2022 | DEBIOPHARM AND ASPEN PARTNER TO LAUNCH PROSTATE CANCER DRUG TRELSTAR® IN SOUTH AFRICA | LAUSANNE, Switzerland and DURBAN, South Africa, Feb. 1, 2022 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company and Aspen, a South African headquartered multinational pharmaceutical company announced today th... |
| Jan 31, 2022 | Pfizer Inc. - European Commission Approves LORVIQUA (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancer | NEW YORK - Pfizer Inc. (NYSE: PFE) announced that the European Commission (EC) granted marketing authorization for LORVIQUA (lorlatinib, available in the U.S. under the brand name LORBRENA) as monotherapy for the treatment of adult patients... |
| Jan 19, 2022 | Imfinzi plus chemotherapy reduced risk of death by 20% in 1st-line advanced biliary tract cancer | * TOPAZ-1 is the first Phase III trial to show improved survival with an immunotherapy combination in this setting
Combination did not increase discontinuations due to adverse events vs. chemotherapy alone
Positive results from the TOPAZ-1 ... |
| Jan 19, 2022 | AstraZeneca : Imfinzi plus chemotherapy reduced risk of death by 20% in 1st-line advanced biliary tract cancer | PUBLISHED18 January 2022
18 January 2022 22:05 GMT
TOPAZ-1 is the first Phase III trial to show improved survival with an immunotherapy combination in this setting
Combination did not increase discontinuations due to adverse events vs. chem... |
| Jan 18, 2022 | EQRx Announces Two Lancet Oncology Publications of Positive Phase 3 Results of Sugemalimab in Stage III and Stage IV Non-Small Cell Lung Cancer | Results from the pivotal Phase 3 GEMSTONE-301 study demonstrated that sugemalimab, an anti-PD-L1 antibody, improves progression-free survival (PFS) in patients with Stage III non-small cell lung cancer (NSCLC) after sequential or concurrent... |
| Jan 6, 2022 | Knight Therapeutics Inc. Announces Approval of Halaven® in Colombia | MONTREAL, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) announced today that its Colombian affiliate, Biotoscana Farma S.A. has obtained INVIMA approval for Halaven® (eribulin) injection.
H... |
| Jan 4, 2022 | Knight Therapeutics Inc. Announces Approval of Lenvima® in Colombia | MONTREAL, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) announced today that its Colombian affiliate, Biotoscana Farma S.A. has obtained INVIMA approval for Lenvima® (lenvatinib), the orall... |
